Lördag 13 September | 21:36:53 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Alzinova reports strong half-year scientific and financial progress
2025-08-22 13:32:00

Alzinova's journey towards a potential new Alzheimer's treatment has accelerated in 2025. Highlights include positive phase Ib results showing stable antibody levels in both plasma and cerebrospinal fluid, a successful rights issue that secured SEK 30 million, and the submission of an IND application to the FDA for the phase II study of ALZ-101. Tord Labuda, CEO of Alzinova, visited BioStock’s studio to comment on the progress during Q2.

Read the full article at biostock.se:

https://biostock.se/en/2025/08/alzinova-reports-strong-half-year-scientific-and-financial-progress/
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden